Compare Stryker Corporation (SYK) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Tenet Healthcare Corporation — how do they compare? Stryker Corporation trades at $277.33 (market cap $106.24B), while Tenet Healthcare Corporation trades at $263.78 (market cap $20.98B). The key difference: Stryker Corporation is far larger — about 5.1× Tenet Healthcare Corporation's market cap, and Stryker Corporation pays a 1.27% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Tenet Healthcare Corporation for 15 Days on average.
| SYK | THC | |
|---|---|---|
Market Cap | $106.24B | $20.98B |
Volume | 2,982,001 | 428,008 |
Sector | Health | Health |
52-Week High | $388.35 | $280.77 |
52-Week Low | $269.75 | $161.37 |
Typical Hold Time | 21 Days | 15 Days |
Enterprise Value | $117.70B | $32.06B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Tenet Healthcare (THC) trades at $263.78, up 1.52% today, with a bullish technical signal from moving averages and strong fundamental support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 29, 2026. Revenue grew to $21.31B in 2025, with a robust net income margin of 9.9% and high return on equity of 53.31%, while valuation ratios like P/E of 10.07 and EV/EBITDA of 5.75 suggest potential undervaluation.
The outlook is positive, driven by earnings momentum and analyst consensus favoring buys, with a price target of $283.36 offering upside. Risks include reliance on surgical volumes and capital return sustainability, but strong cash flow and efficiency gains support growth. Investors should weigh solid fundamentals against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
